A novel therapeutic vaccine targeting the soluble TNFα receptor II to limit the progression of cardiovascular disease: AtheroVax™

The burden of atherosclerotic cardiovascular disease contributes to a large proportion of morbidity and mortality, globally. Vaccination against atherosclerosis has been proposed for over 20 years targeting different mediators of atherothrombosis; however, these have not been adequately evaluated in...

Full description

Bibliographic Details

Published in:	Frontiers in Cardiovascular Medicine
Main Authors:	Patrick L. Iversen, Nicholas Kipshidze, Nodar Kipshidze, George Dangas, Eduardo Ramacciotti, Zurab Kakabadze, Jawed Fareed
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-07-01
Subjects:	atherosclerotic cardiovascular disease tumor necrosis factor alpha TNFRII soluble TNFRII therapeutic vaccine peptide vaccine
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2023.1206541/full